COMMUNIQUÉS West-GlobeNewswire

Virbac : Déclaration d'actions et de droits de vote 05/2026
08/06/2026
DÉCLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Amphista Therapeutics announces FDA clearance of IND application for AMX-883, its lead Targeted Glue™ degrader for acute myeloid leukaemia
08/06/2026
Amphista to initiate its first clinical trial for AMX-883, a potent, orally bioavailable DCAF16-dependent degrader of BRD9, for acute myeloid leukaemia (AML) in H2 2026 The Phase 1 monotherapy dose-escalation and [...]
Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204
08/06/2026
CALGARY, Alberta, June 08, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF ), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug [...]
Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026
08/06/2026
WALTHAM, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today [...]
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
08/06/2026
Late-breaking presentation reports a proteomic analysis of heart failure biomarkers during lorundrostat treatment RADNOR, Pa., June 08, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a [...]
Ceribell Announces New Critical Care Medicine Publication Reinforcing Link Between Seizure Burden Measured by Clarity AI Algorithm and Neurological Outcomes
08/06/2026
Study published in leading critical care journal shows that higher AI-detected seizure burden is associated with increased odds of disability, further demonstrating the utility of the Ceribell System as a clinical [...]
Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program
08/06/2026
Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values Deadline for Applications is August 3, 2026 SOUTH SAN FRANCISCO, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, [...]
Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal
08/06/2026
BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW) , a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary [...]
Standard BioTools and Treeline Biosciences Announce Merger Agreement
08/06/2026
Combined company to operate as Treeline Biosciences, advancing a deep pipeline of small molecule inhibitors, protein degraders and targeted therapy antibody-drug conjugates Company to be led by Treeline CEO and co- [...]
Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
08/06/2026
MINNEAPOLIS and BRISBANE, Australia, June 08, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced today that it has received full regulatory [...]
Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives
08/06/2026
Agreement with second leading group purchasing organization (GPO), effective June 1, 2026, provides access to approximately 17 million additional U.S. commercial lives (10% of the ~177 million commercial lives in the U. [...]
Virbac : Declaration of the number of shares and voting rights 05/2026
08/06/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses
08/06/2026
KT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and clinically active therapies in multiple preclinical lupus models KT-579 Phase 1 healthy volunteer trial ongoing, with data [...]
Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
08/06/2026
Initial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with vopimetostat and daraxonrasib showed 6-month PFS rate of 90% (median PFS not yet reached) suggesting durability of [...]
Sequel Presents Pivotal Trial of the twiist™ Automated Insulin Delivery System in Adults with Insulin-Treated Type 2 Diabetes at the ADA 86th Scientific Sessions
08/06/2026
Investigational study marks Sequel’s first pivotal data in type 2 diabetes, the largest population on insulin therapy and one of the most under-served by automated insulin delivery NEW ORLEANS, June 08, 2026 (GLOBE [...]
Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA
08/06/2026
MIPLYFFA patent submitted for Orange Book listing, with patent protection to 2041 Separately filed patent term extension remains pending with the U.S. Patent and Trademark Office BOSTON, June 08, 2026 (GLOBE NEWSWIRE [...]
Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting
08/06/2026
BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc ., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW) , a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary [...]
MitoRx Therapeutics presents promising preclinical data on MTRX31, a mitochondrial-targeted small molecule for metabolically unhealthy obesity, at the American Diabetes Association’s 2026 Scientific Sessions
08/06/2026
MTRX31 led to a highly significant decrease in fat mass after two-months chronic dosing in a preclinical diet-induced obesity mouse model performed at thermoneutrality Weight loss and reduction of fat deposits in [...]
Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission
08/06/2026
European regulatory filing supports planned 2026 initiation of Phase 2b study of Teverelix® in an underserved population representing ~$4 billion annual market opportunity PHILADELPHIA, June 08, 2026 (GLOBE NEWSWIRE [...]

Pages